#2 - Johnson & Johnson (NYSE:JNJ)
News about a Covid-19 vaccine will continue to attract investors. Yes, Johnson & Johnson (NYSE:JNJ) has a promising candidate that seems to check many of the boxes (i.e. single dose, long-term immunity, stores, and ships at refrigerator temperatures). And the company is conducting what is considered a “massive” 60,000 subject clinical trial. Should that go well, JNJ could be the leader in the clubhouse.
However, if you accept the premise that there may be more than one vaccine, then don’t sleep on Moderna (NYSE:MRNA). The company is attempting to bring the first successful messenger RNA (mRNA) vaccine licensed for human use. The science behind the vaccine is promising but unproven. Nevertheless, Moderna is receiving funds via Operation Warp Speed (OWS) and it’s a reasonable bet that they will be given a bite at the apple.
But even if they are shut out of the Covid-19 vaccine, getting a vaccine through clinical trials would be a proof of concept for their process. And that’s good news for the other candidates in its pipeline.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Read More - Current Price
- $146.82
- Consensus Rating
- Hold
- Ratings Breakdown
- 6 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $175.86 (19.8% Upside)
